BIO.News Newsletter

The response to Friday’s mifepristone ruling continues, as BIO joined an amicus brief calling for suspension of the ruling and explains in STAT News how it’s just the latest assault on FDA’s authority. In better news, partnering ahead of the BIO International Convention is moving at a record pace—we have details. (581 words, 2 minutes, 54 seconds)

More than 400 biotech execs and companies oppose the Texas ruling on mifepristone, and the administration announces the $5B follow-up to Operation Warp Speed. Plus, today’s new episode of the I am BIO Podcast looks at what’s next for CRISPR. (587 words, 2 minutes, 56 seconds)

Friday’s mifepristone ruling in Texas is an assault on the FDA’s approval process, says BIO—here’s what happened. Plus, Mexico is seemingly doubling down on the biotech corn ban as the possibility of a formal dispute looms. (497 words, 2 minutes, 29 seconds)

On World Health Day, we look at 75 years of major health milestones—and the work still needed to ensure health equity and the health of the planet. Plus, we recap BIO’s panel at the World Vaccine Congress. (414 words, 2 minutes, 4 seconds)

A new report explains how drug price controls in the Inflation Reduction Act could harm R&D for orphan drugs—plus, why there’s no need to stockpile chocolate bunnies this weekend, thanks to biotech. (545 words, 2 minutes, 43 seconds)

We look at two recent polls (including one from BIO) showing how Americans feel about pandemic preparedness, and the promising outlook for CRISPR in agriculture. (554 words, 2 minutes, 46 seconds)

We have details on Biden’s National Cancer Plan—and why price controls may stop innovation in its tracks. Plus, everyone’s talking about AI, so we look at how biotech’s using it to make tasty protein alternatives. (499 words, 2 minutes, 29 seconds)

After a whirlwind week on Capitol Hill, Congress is in recess. Today, we explore how CRISPR might reverse the damage after a heart attack and how plant-based bioplastics can reduce the waste after a snack attack. (498 words, 2 minutes, 29 seconds)

A busy week in Washington wraps with a Senate hearing on PBMs, House hearings on agriculture, and the final day of the USITC’s hearing on the expansion of the COVID IP waiver. (748 words, 3 minutes, 44 seconds)

We’ve packed a lot in today’s issue: BIO’s testimony on the TRIPS waiver at the USITC, a new poll that shows support from voters in both parties for pandemic preparedness, and a recap of CSBA’s Capitol Hill fly-in—plus, a few things you missed on the Hill. (599 words, 2 minutes, 59 seconds)